About DnaNudge
DnaNudge is a company based in London (United Kingdom) founded in 2015 by Maria Karvela and Christofer Toumazou. DnaNudge has raised $60 million across 1 funding round from investors including Julius Baer and Ventura Capital. The company has 79 employees as of July 31, 2023. DnaNudge operates in a competitive market with competitors including 10X Genomics, Element Biosciences, Stratec Biomedical, Laverock Therapeutics and Synplogen, among others.
- Headquarter London, United Kingdom
- Employees 79 as on 31 Jul, 2023
- Founders Maria Karvela, Christofer Toumazou
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Dnanudge Limited
- Date of Incorporation 28 Jul, 2015
- Jurisdiction LONDON, ENGLAND
-
Annual Revenue
$1.07 M (USD)-88as on Jul 31, 2023
-
Net Profit
-$16.54 M (USD)-497as on Jul 31, 2023
-
EBITDA
-$17.09 M (USD)-500as on Jul 31, 2023
-
Total Equity Funding
$60 M (USD)
in 1 rounds
-
Latest Funding Round
$60 M (USD), Series A
Aug 24, 2021
-
Investors
Julius Baer
& 1 more
-
Employee Count
79
as on Jul 31, 2023
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of DnaNudge
Unlock access to complete
Unlock access to complete
Funding Insights of DnaNudge
DnaNudge has successfully raised a total of $60M through 1 strategic funding round. The most recent funding activity was a Series A round of $60 million completed in August 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in DnaNudge
DnaNudge has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Julius Baer and Ventura Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on tech sectors
|
Locked | Locked | Locked | |
|
Private Banking firm offering wealth management services
|
Locked | Locked | Locked |
Investor details for DnaNudge
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by DnaNudge
Investment portfolio details for DnaNudge
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - DnaNudge
Detailed financials for DnaNudge
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Dnanudge Comparisons
Peer comparison for DnaNudge
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of DnaNudge
DnaNudge operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as 10X Genomics, Element Biosciences, Stratec Biomedical, Laverock Therapeutics and Synplogen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Instrument systems for genomic research and sequencing libraries are developed.
|
|
| Locked | Locked | Locked |
Benchtop DNA sequencers are developed for research and diagnostic uses.
|
|
| Locked | Locked | Locked |
Provider of automated analyzer systems, data management software, and solutions for IVD sample preparation
|
|
| Locked | Locked | Locked |
Next-generation programmable cell therapies are developed using GEiGS technology.
|
|
| Locked | Locked | Locked |
DNA synthesis technology is developed using microbial methods.
|
Detailed competitors of DnaNudge
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Dnanudge
Complete news archive for DnaNudge
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DnaNudge
DnaNudge was founded in 2015 and raised its 1st funding round 6 years after it was founded.
DnaNudge is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Christofer Toumazou is the current CEO of DnaNudge. They have also founded this company.
DnaNudge is a funded company, having raised a total of $60M across 1 funding round to date.
As of Jul 31, 2023, the latest employee count at DnaNudge is 79.
Annual revenue of DnaNudge is $1.07M as on Jul 31, 2023.
DnaNudge was founded in 2015 in London, United Kingdom, as a provider in the health technology sector. Genetic diagnosis is enabled through a lab-on-chip wearable system that processes cheek swabs in disposable cartridges via a tabletop NudgeBox. DNA and lifestyle data are analyzed to offer real-time guidance on personalized food and skincare choices. A Wearable DnaBand is synced with a smartphone app, supporting barcode scanning for product compatibility indicators.
DnaNudge's top competitors include 10X Genomics, Element Biosciences and Laverock Therapeutics.
DnaNudge has 2 investors. Key investors include Julius Baer, and Ventura Capital.